Solving Kids’ Cancer is a non-profit organization with a track record of funding novel clinical research for children diagnosed with high-risk solid tumors specifically neuroblastoma, brain tumors and sarcomas.
The Therapeutic Development Initiative (TDI) is SKC’s strategic platform for the implementation of our research agenda as well as the vehicle for reviewing and prioritizing submitted research proposals. The TDI’s goal is to support innovative clinical studies that are high on the risk/reward spectrum while, at the same time, investigating these research questions efficiently and effectively. Priority is given to proposals that introduce therapeutic agents and modalities, which are first-in-children and have a strong potential to improve treatment outcomes. Funding award amounts generally range from $50,000 to $600,000 depending on the scope of the study.
Proposals are accepted and reviewed throughout the year on a rolling basis.